{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:45:49Z","timestamp":1791747949848,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203787"],"award-info":[{"award-number":["82203787"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clim.2026.110762","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:03:35Z","timestamp":1787241815000},"page":"110762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["T-cell activation profiles predict outcomes of neoadjuvant therapy in breast cancer"],"prefix":"10.1016","volume":"288","author":[{"given":"Chaoni","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saixiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110762_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103851","article-title":"Inequality in breast cancer: global statistics from 2022 to 2050","volume":"79","author":"Liao","year":"2025","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0010","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1186\/s12885-024-12974-4","article-title":"Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study","volume":"24","author":"Ran","year":"2024","journal-title":"BMC Cancer"},{"issue":"16_suppl","key":"10.1016\/j.clim.2026.110762_bb0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.2024.42.16_suppl.541","article-title":"Short-term risk of recurrence in patients (pts) with HR+\/HER2\u2212 early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): a meta-analysis","volume":"42","author":"Curigliano","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41523-025-00824-w","article-title":"A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials","volume":"11","author":"Potter","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0025","doi-asserted-by":"crossref","first-page":"36220","DOI":"10.1038\/s41598-025-20216-1","article-title":"Impact of neoadjuvant and adjuvant chemotherapy on breast cancer prognosis in a propensity score matched population","volume":"15","author":"Xu","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.clim.2026.110762_bb0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial","volume":"37","author":"Harbeck","year":"2025","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-024-00712-9","article-title":"Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative","volume":"10","author":"Shin","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"48","key":"10.1016\/j.clim.2026.110762_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202509930","article-title":"Targeting mast cell activation and MIF-mediated remodelling enhances chemotherapy response in pancreatic cancer","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci."},{"issue":"8","key":"10.1016\/j.clim.2026.110762_bb0045","article-title":"Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Cell Rep Med"},{"issue":"9","key":"10.1016\/j.clim.2026.110762_bb0050","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41523-023-00565-8","article-title":"Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with miller-Payne grade 4 following neoadjuvant chemotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0060","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2026.110762_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216656","article-title":"Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing","volume":"585","author":"Jia","year":"2024","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.clim.2026.110762_bb0070","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.clim.2026.110762_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics15192492","article-title":"Assessment of tumor-infiltrating lymphocytes in triple-negative breast cancer: interobserver variability and contributing factors","volume":"15","author":"Baharun","year":"2025","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.clim.2026.110762_bb0080","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200921","article-title":"Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells","volume":"218","author":"Lucca","year":"2021","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0085","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2025.5762","article-title":"Beyond the tumor microenvironment: orchestrating systemic T-cell response for next-generation cancer immunotherapy (review)","volume":"67","author":"Lyu","year":"2025","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.clim.2026.110762_bb0090","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.3389\/fimmu.2018.02605","article-title":"HLA-DR in cytotoxic T lymphocytes predicts breast Cancer patients\u2019 response to neoadjuvant chemotherapy","volume":"9","author":"Saraiva","year":"2018","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2026.110762_bb0095","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.21873\/anticanres.17281","article-title":"CD8-positive T-cells are key immune cells for predicting the therapeutic effect of neoadjuvant chemotherapy in triple-negative breast Cancer","volume":"44","author":"Uenaka","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clim.2026.110762_bb0100","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.17667","article-title":"The potential role of CD8+cytotoxic T lymphocytes and one branch connected with tissue-resident memory in non-luminal breast cancer","volume":"12","author":"Zhao","year":"2024","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.clim.2026.110762_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032969","article-title":"Triple-negative breast Cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review","volume":"24","author":"van den Ende","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2026.110762_bb0115","article-title":"In situ genetically engineering nanosystem for reversing immunosuppression of cancer-associated fibroblasts in breast cancer radiotherapy","volume":"327","author":"Qiu","year":"2025","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.clim.2026.110762_bb0120","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41416-023-02432-6","article-title":"The heterogeneity of tumour immune microenvironment revealing the CRABP2\/CD69 signature discriminates distinct clinical outcomes in breast cancer","volume":"129","author":"Mei","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2026.110762_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2020.05.014","article-title":"Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: analysis of 244 stage I-III patients treated with standard therapy","volume":"136","author":"Dieci","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-018-4825-8","article-title":"Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study","volume":"171","author":"O\u2019Loughlin","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.clim.2026.110762_bb0135","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.21873\/anticanres.13232","article-title":"A standardized evaluation method for FOXP3+Tregs and CD8+T-cells in breast carcinoma: association with breast carcinoma subtypes, stage and prognosis","volume":"39","author":"Papaioannou","year":"2019","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.clim.2026.110762_bb0140","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.clim.2026.110762_bb0145","article-title":"The liquid biopsy consortium: challenges and opportunities for early cancer detection and monitoring","volume":"4","author":"Batool","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.clim.2026.110762_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2025.115062","article-title":"Biosensor-driven innovation in CA19-9 cancer biomarker detection: current trends, technical challenges, and future directions towards point-of-care diagnostics","volume":"217","author":"Wang","year":"2025","journal-title":"Microchem. J."},{"key":"10.1016\/j.clim.2026.110762_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.217242","article-title":"Advances in cancer biomarkers: current detection strategies and challenges","volume":"549","author":"Liu","year":"2026","journal-title":"Coord. Chem. Rev."},{"issue":"10","key":"10.1016\/j.clim.2026.110762_bb0160","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2013.07.006","article-title":"Is CD69 an effective brake to control inflammatory diseases?","volume":"19","author":"Gonz\u00e1lez-Amaro","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.clim.2026.110762_bb0165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3343\/alm.2024.0178","article-title":"CD69 expression is negatively associated with T-cell immunity and predicts antiviral therapy response in chronic hepatitis B","volume":"45","author":"Gu","year":"2025","journal-title":"Ann. Lab. Med."},{"issue":"2","key":"10.1016\/j.clim.2026.110762_bb0170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.alit.2019.11.002","article-title":"Increased CD69 expression on activated eosinophils in eosinophilic chronic rhinosinusitis correlates with clinical findings","volume":"69","author":"Yun","year":"2020","journal-title":"Allergol. Int."},{"key":"10.1016\/j.clim.2026.110762_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2026.110762_bb0180","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1600-6143.2004.00570.x","article-title":"HLA-DR matching and immune regulation","volume":"4","author":"Game","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0185","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s42003-025-07897-0","article-title":"ZDHHC9-mediated CD38 palmitoylation stabilizes CD38 expression and promotes pancreatic cancer growth","volume":"8","author":"Guo","year":"2025","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.clim.2026.110762_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020309","article-title":"IFN-\u03b3 and CD38 in Hyperprogressive Cancer development","volume":"13","author":"Angelicola","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0195","doi-asserted-by":"crossref","first-page":"14424","DOI":"10.1038\/s41598-021-93807-3","article-title":"HLA-DR cancer cells expression correlates with T cell infiltration and is enriched in lung adenocarcinoma with indolent behavior","volume":"11","author":"Senosain","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0200","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1252013","article-title":"Immunosuppressive CD14(+)HLA-DR(lo\/neg) monocytes are elevated in pancreatic cancer and \u201cprimed\u201d by tumor-derived exosomes","volume":"6","author":"Javeed","year":"2017","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.clim.2026.110762_bb0205","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10753-012-9496-8","article-title":"CD4(+)CD25 (+)CD127 (low\/\u2212) T cells: a more specific Treg population in human peripheral blood","volume":"35","author":"Yu","year":"2012","journal-title":"Inflammation"},{"issue":"11","key":"10.1016\/j.clim.2026.110762_bb0210","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/jcp.25016","article-title":"Treg(s) in Cancer: friends or foe?","volume":"230","author":"Wolf","year":"2015","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.clim.2026.110762_bb0215","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","article-title":"CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity","volume":"56","author":"Moreno Ayala","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2026.110762_bb0220","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fimmu.2020.00676","article-title":"Inducers, attractors and modulators of CD4(+) Treg cells in non-small-cell lung Cancer","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110762_bb0225","doi-asserted-by":"crossref","first-page":"1574327","DOI":"10.3389\/fimmu.2025.1574327","article-title":"The role of Treg cells in colorectal cancer and the immunotherapy targeting Treg cells","volume":"16","author":"Yu","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2026.110762_bb0230","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2026.110762_bb0235","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0240","doi-asserted-by":"crossref","first-page":"30789","DOI":"10.1038\/s41598-025-16112-3","article-title":"ITK overexpression enhances T cell cytotoxicity against DLBCL through the TCR-ca(2+)-calcineurin-NFAT-IFN-\u03b3 pathway","volume":"15","author":"Liu","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0245","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1186\/s12885-025-15022-x","article-title":"Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response and prognosis in breast cancer: a multicenter retrospective study based on Chinese population","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"issue":"39","key":"10.1016\/j.clim.2026.110762_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000044743","article-title":"The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer","volume":"104","author":"Yeti\u015fyi\u011fit","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.clim.2026.110762_bb0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13058-024-01848-z","article-title":"Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer","volume":"26","author":"Leon-Ferre","year":"2024","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.clim.2026.110762_bb0260","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-022-06791-1","article-title":"Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer","volume":"197","author":"Wang","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.clim.2026.110762_bb0265","first-page":"3091","article-title":"Clinical significance of regulatory T cells and T lymphocyte subsets in peripheral blood in neoadjuvant chemotherapy for breast cancer","volume":"13","author":"Mao","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.clim.2026.110762_bb0270","article-title":"Circulating T-cell repertoires correlate with the tumor response in patients with breast cancer receiving neoadjuvant chemotherapy","volume":"6","author":"Cai","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.clim.2026.110762_bb0275","first-page":"rs.3.rs","article-title":"Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer","author":"Balko","year":"2025","journal-title":"Res. Sq. [Preprint]"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:48:55Z","timestamp":1791744535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":55,"alternative-id":["S1521661626001002"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110762","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell activation profiles predict outcomes of neoadjuvant therapy in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110762"}}